Antibiotice (BSE:ATB) Total Receivables: lei379.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:ATB Antibiotice SA BSE:ATB
79 GF Score
Price lei2.11
GF Value lei2.18
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Antibiotice Total Receivables?

Antibiotice BSE:ATB +0.48% 79 Total Receivables is lei379.3 Mil as of Jun. 2026. GuruFocus rates BSE:ATB with a GF Score™ of 79/100 and a GF Value™ of lei2.18 (Fairly Valued). The stock has 7 warning signs investors should review.

Antibiotice's Total Receivables for the quarter that ended in Jun. 2026 was lei379.3 Mil.

Antibiotice Total Receivables Historical Data

* Premium members only.

The historical data trend for Antibiotice's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibiotice Total Receivables Chart

Antibiotice Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.75 207.28 233.91 284.54 307.15

Antibiotice Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 337.41 311.88 307.15 342.72 379.30
BSE:ATB
79GF Score
Antibiotice SA BSE:ATB
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibiotice Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of lei379.3 Mil mean?
Antibiotice (BSE:ATB) has a Total Receivables of lei379.3 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Antibiotice and its competitors.
Is Antibiotice's Total Receivables too high?
Antibiotice's current Total Receivables is lei379.3 Mil. Overall, Antibiotice has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Total Receivables compare to ZTS and UTHR?
Antibiotice's Total Receivables of lei379.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Antibiotice and its competitors. Antibiotice's current Total Receivables is lei379.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Based on GuruFocus' analysis, Antibiotice (BSE:ATB) is currently considered Fairly Valued. The stock's GF Value™ is lei2.18, compared to a current price of lei2.11 — trading 3.2% below its estimated fair value. The current Total Receivables is lei379.3 Mil. Antibiotice's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Antibiotice (BSE:ATB), the current Total Receivables is lei379.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antibiotice (BSE:ATB) Overvalued in 2026?

Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued. The current stock price of lei2.11 is trading 3.2% below its estimated GF Value™ of lei2.18. GuruFocus considers Antibiotice to be Fairly Valued.

Key valuation signals for BSE:ATB:

  • Total Receivables: lei379.3 Mil
  • GF Value™: lei2.18 vs. price of lei2.11 (3.2% below fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the BSE:ATB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antibiotice Business Description

Address 1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
79GF Score

Get the complete analysis for BSE:ATB

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei2.11
Price
lei2.18
GF Value